Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
NCT06017284

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Led by Fudan University · Updated on 2023-11-24

100

Participants Needed

1

Research Sites

160 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.

CONDITIONS

Official Title

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand and sign written informed consent
  • Age between 18 and 80 years
  • ECOG performance status 0-2
  • Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma
  • Adequate organ function based on lab tests
  • At least one measurable lesion per RECIST criteria
  • Expected survival of 3 months or more
  • Women of childbearing potential and men agree to use effective contraception during the study
Not Eligible

You will not qualify if you...

  • Prior anti-tumor therapy received
  • Diagnosis of pancreatic cancer other than adenocarcinoma
  • Inflammation of digestive tract (e.g., pancreatitis, cholecystitis, cholangitis)
  • Pregnant or nursing women
  • Severe or uncontrolled diseases affecting compliance or safety (e.g., active infections, uncontrolled diabetes, severe heart failure, recent heart attack, unstable arrhythmia or angina, recent stroke)
  • History of allergic reactions to gemcitabine, nab-paclitaxel, or similar agents
  • Other serious illnesses that may affect treatment safety
  • Unwillingness or inability to comply with study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

Loading map...

Research Team

Y

Ying Yang, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here